Regional Executives from HR, BioManufacturing, Academia and Government will discuss how your company can compete for the top talent and what with other markets and not with each other.
Shiva Fritsch, Senior Vice President, Human Resources, RegenxBIO; Antonio Moreira, Ph.D, Vice Provost for Academic Affairs, UMBC; Bret Schreiber, Senior Director, Office of BioHealth & Life Sciences, Maryland Commerce, Craig Malzahn Vice President and Site Director of Rockville Biopharm. Moderator: Chris Frew, Workforce Genetics
Senior Vice President
Ms. Fritsch has 20+ years of experience in research and development, biopharmaceutical industry and human resources. For the past 10 years, Ms. Fritsch has been instrumental in serving organizations by leading with a focus on Organization and Leadership Development.
Prior to joining REGENXBIO, Ms. Fritsch held senior Human Resources roles with Human Genome Sciences, Inc., Howard Hughes Medical Institute, and most recently, Ms. Fritsch was the Senior Director of Talent Management at Novavax, Inc. In her roles, she served as a member of the HR Senior Leadership team, directing and leading all activities related to Talent Acquisition, Organization and Talent Development, as well as implementing HR Business Partner models for Howard Hughes Medical Institute and Novavax, Inc.
Ms. Fritsch graduated from Bryn Mawr College with a B.A. in Biology and Neurobiology and received her MBA from the Robert H. Smith School of Business at the University of Maryland.
Antonio R. Moreira, PhD
University of Maryland
Vice Provost, Academic Affairs
Antonio (Tony) R. Moreira, PhD is Vice Provost for Academic Affairs at the University of Maryland, Baltimore County (UMBC) and is responsible for academic affairs matters within the Provost’s Office. In addition to his administrative responsibilities, he has maintained an active teaching and research program in bioprocessing, regulatory science and engineering. He frequently presents short courses in biotechnology topics for industry as well as regulatory agencies.
Dr. Moreira has over 30 years experience in the biopharma sector and spent nearly 10 years in management positions in the private sector with International Flavors and Fragrances and with Schering-Plough Corp. (now Merck). He has been an ISPE Member for over 20 years and is the founding President of the ISPE Chesapeake Bay Area Chapter. He has been a member of the International Board of Directors of ISPE and is currently on the Board of the ISPE Foundation.
He has also been active in the Parenteral Drug Association, Biotechnology Industry Organization (Chairman of the Council of Biotechnology Centers), American Chemical Society and American Institute of Chemical Engineers. He is published in many peer-reviewed publications, is a co-editor for several books and is a frequent speaker at national and international conferences. Dr. Moreira holds a BS in Chemical Engineering from the University of Oporto, an MS and PhD in Chemical and Biochemical Engineering from the University of Pennsylvania.
Office of BioHealth & Life Sciences
Bret Schreiber, MD Commerce Prior to the Department of Commerce, Bret Schreiber has worked for over 20 years in the field of government and community relations, driving policy and economic development initiatives and developing strong ties to local, state and national legislators. As Senior Director for the Office of BioHealth and Life Sciences, Schreiber is working to establish Maryland as the Nation’s premier ecosystem for the BioHealth and Life Science industry. Previously, as Director of Education and Innovation for the Maryland Department of Commerce, Schreiber worked with Maryland’s Colleges and Universities, and the State’s innovators, entrepreneurs and startups to leverage their economic potential and impact on Maryland’s economic vitality.
Schreiber also served as Director of Governmental and Community Relations for Harford County Maryland, Vice-president of the Maryland Independent College and University Association (MICUA), leading policy development and involved in organizational operations for Maryland’s 12 independent nonprofit higher education institutions, and also spent 10 years working with the Johns Hopkins Institutions helping to plan, implement, and manage the Johns Hopkins Institutions’ strategic State agenda with elected and appointed officials.
A Harford County resident, Mr. Schreiber holds a degree in political science from Johns Hopkins University.
Vice President and Site Director
GSK, Rockville Biopharm
Craig Malzahn was appointed Site Director of the GSK Rockville Biopharm site in December 2016 after serving six months as interim site director. He had become Director of BioPharmaceutical Technology (BPT) in April 2016 and assumed acting Site Director responsibilities in July 2016. Prior to this assignment, he was the Director, Supply Chain Operations in Rockville and for two years at Upper Merion Biopharm as well.
Craig has more than 20 years of manufacturing, technical, and supply chain experience in biopharmaceuticals and vaccines. Prior to joining GSK, he was Senior Director of Supply Chain for Human Genome Sciences, Inc. during which time he led the transformation from a clinical logistics team to an end-to-end commercial supply chain and oversaw the launch of Benlysta and raxibacumab. From 2005 to 2011, he led the Raxibacumab Core Team and delivery of anthrax anti-toxin doses to the Strategic National Stockpile, negotiated and managed the procurement relationship with the U.S. Government.
With Baxter Bioscience, he led Pilot Plant Operations for clinical vaccine production and with North American Vaccine, Inc., he was a manufacturing manager and fermentation manufacturing associate. Craig earned an M.S. degree in Biotechnology from Johns Hopkins University and a B.S. in Biology from Virginia Tech.
Single Use technology has been used successfully for decades to improve the flexibility of existing stainless steel manufacturing plants. More recently, entire production facilities are being designed with single use flow paths. AstraZeneca’s Director-level process and manufacturing team leaders will discuss AZ’s journey from the introduction of single use through current production strategies and the establishment of a single use management system.
AZ will discuss the challenges encountered on initial single use technology application and how AZ teams have addressed major issues along the way. AZ will chart where the company is headed to ensure reliability and security of supply. Finally, AZ will discuss our participation in BioPhorum, a consortium who has a working group charged with the goal to make single use technologies as reliable and understood as stainless steel.
Matt Rittler is currently a Senior Scientist in the Manufacturing Sciences & Technology (MS&T) department at AstraZeneca’s Frederick Manufacturing Center. He has extensive experience in protein purification sciences—with over 15 years’ experience in process development and manufacturing of biologics. He leads the extractables and leachables team at FMC and is a subject matter expert for single-use technologies at the site. Prior to joining AstraZeneca, Matt has held various positions in industry, academia, and the government. Matt has a Ph.D. in biomedical engineering from Virginia tech, along with a bachelor’s degree in biochemistry from McDaniel College, in Westminster, MD.
Biotech Process Engineer
Steve Granger currently leads the global process engineering team for AstraZeneca’s biologics manufacturing network. He has been in the process engineering field for nearly 25 years, with over 15 years’ experience in the design, construction, startup, and troubleshooting in biologics drug substance facilities. Prior to joining AstraZeneca, Steve has held various technical / process engineering leadership positions with DSM, Bristol-Myers Squibb, Abbott, and AbbVie. Steve has a bachelor’s degree in chemical engineering from Rensselaer Polytechnic Institute in Troy NY, along with a master’s degree in bioscience administration from Worcester Polytechnic Institute in Worcester MA.
Panelists from different sectors of the industry will discuss regional trends and the state of the market. Discussion will cover topics on availability of commercial lab space and incubator space to facility design and planning.
Judy Costello is the Managing Director of Economic Development for BioHealth Innovation, Inc. (BHI). A longtime supporter of the region’s entrepreneur and start-up communities, Judy Costello joined BioHealth Innovation in August 2017. She previously served as Director of the Maryland Department of Commerce's Office of BioHealth and Life Sciences and Deputy Director of the department's BioMaryland Center.
Prior to her employment with the State of Maryland, she worked for fifteen years for the Business Alliance organizing venture pitch forums, entrepreneur bootcamps, tech transfer showcases, educational seminars, and other programs connecting entrepreneurs, faculty innovators, students, and industry leaders in Maryland, DC and Virginia with each other and with those providing funding and other resources to young companies.
Before joining the Business Alliance, Costello held positions in economic development, financial services marketing, and university public relations. She is a graduate of Georgetown University, holds a MBA from Loyola University in Maryland, and is an active member of many groups supporting entrepreneurship and innovation focused economic development in the region.
Senior Vice President
Matt Brady concentrates his efforts on providing comprehensive real estate services for scientific companies. Over the past 16 years Matt has successfully helped his clients complete over 3,000,000 square feet of commercial real estate transactions with uses including: R&D laboratories, GMP-compliant manufacturing, animal facilities, and diagnostic labs.
He has extensive experience in executing complex projects consisting of leasing, strategic facility planning/consulting, acquisitions, and financing. Matt’s ability to pair his in-depth knowledge of the lab market and understanding of his clients’ functional requirements have enhanced his ability to add an additional level of value to transactions through skilled and professional advice, negotiating skills, and unique technical aptitude.
Chief Executive Office,
As Chief Executive Officer of RoosterBio Inc., Margot Connor brings over 25 years of diversified Life Science industry experience which includes executive level accountability for business operations, corporate development and M&A.
Margot joined RoosterBio after 4 years of operating her private consulting company specializing in Corporate Development and M&A. Over the course of her career M&A activities, she was involved in approximately 20 transactions valued at $1.5 billion.
While at Lonza Group in Basel, Switzerland, Margot was the Head of Corporate Communications and Investor Relations. Following this international position within Lonza, she was appointed Vice President and Head of Business Development at Lonza Walkersville, MD USA. Her continued tenure with Lonza returned to the corporate level, assigned as Director of Corporate Development.
Prior to this, Margot led the global growth of several businesses, which included P&L responsibility. She has held senior positions in business management, strategic marketing and business development with companies such as FMC, Chr. Hansen and Unilever.
Marco A. Chacón, Ph.D
Assistant Vice President of Industry Alliances
at the University of Maryland, Baltimore
As a seasoned biopharmaceutical executive and entrepreneur, Dr. Chacón works with the leadership team at UMB leading special projects to grow the BioPark tenant base and to strengthen the University’s research collaborations with industry.
Dr. Chacón is the Founder and Chairman of Paragon Bioservices, Inc., a Contract Development and GMP Manufacturing Organization (CDMO) located at the University of Maryland BioPark in Baltimore. With nearly 400 employees and approximately 300k square feet of space, Paragon specializes in the development and GMP manufacturing of viral vectors and vaccines.
Dr. Chacón is also the Founder of IRAZÚ Biodiscovery, a regenerative medicine company seeking to develop therapeutic interventions to induce hypoxia tolerance and neuroprotection as described in experimental models of caloric restrictions and hibernation, as well as during the neonatal period in mammals. Dr. Chacón’s academic interests include control of metabolism, oxygen homeostasis and the regenerative potential of tissues and Organs.
Dr. Chacón received a B.S. degree from Youngtown State University and a Ph.D. Degree from the University of Maryland, College Park. He currently serves on the Board of Trustees of the UMB Foundation and was appointed in 2016 to the Life Sciences Advisory Board by Governor Lawrence J. Hogan, Jr.
Patricia Larrabee, MS
Pat Larrabee is the Founder and President of Facility Logix, an owner’s representative and management consulting firm for biotechnology and life sciences companies. With more than 30 years of experience in the biotechnology industry, Pat applies biotech and facility management expertise to address the facility-related needs of biotechnology companies, public and private institutions, economic development organizations and commercial real estate firms and developers. She advises clients across the country as both an owner’s rep and project manager for major biotech and life sciences facility expansions.
Many growing life science clusters trust Facility Logix to help plan and develop communities of innovation and biotech ecosystems that attract industry and develop the workforce. Facility Logix offers facility project management, feasibility studies, and market positioning/strategic operational analyses as core services while facilitating collaboration with industry partners and providing value-add to brokers and commercial real estate firms. The firm serves clients such as Johns Hopkins University, United Therapeutics, bluebird bio, George Mason University, Integrated Biotherapeutics, Eisai, MaxCyte, the Mayo Clinic, and the Wisconsin Alumni Research Foundation.
Whether you are entirely new to the industry and trying to figure out how terms like process development, mammalian cell lines, and protein purification apply to what your company does, or you’re currently working in a GMP environment and looking for a way to grow your skills and knowledge to advance your career, this program is for you.
Kevin Knapstein, Manager
Bioprocess Scale-Up Facility
UMD Biotechnology Research and Education Program
Kevin runs the Bioprocess Scale-Up Facility and oversees bacterial and yeast fermentation contract research. He has worked with local biotech companies as well as several others both foreign and domestic providing scale-up and process development. He has over 15 years of experience in cell propagation, process development, upstream processing and downstream processing.
Kevin has helped develop course curriculum for 4 undergraduate courses and one graduate course in bioengineering. In addition, he has aided with workforce training and mentoring for 11 years. He has been responsible for placing many students in the local biotech industry through his lab or courses he teaches. Kevin currently teaches two bioengineering courses based on pharmaceutical production and bioprocess engineering. Prior to working in the BSF, he worked as a bioprocess engineer at Human Genome Sciences working in downstream process development. Kevin has a B.S. in Biological Resources Engineering and Physiology and a Masters in Bioengineering from the University of Maryland.
Mary Ellen Clark
Associate Director, Manufacturing